Searchable abstracts of presentations at key conferences on calcified tissues
Bone Abstracts (2015) 4 OC19 | DOI: 10.1530/boneabs.4.OC19

ICCBH2015 Oral Communications (1) (22 abstracts)

The VINE study: vitamin D in newborns: a randomized controlled trial comparing daily and bolus supplementation in breastfed infants of vitamin D deficient mothers

Julie Huynh 1 , Thao Lu 1 , Danny Liew 3 , James Doery 4, , Ronald Tudball 4 , Madeleine Jona 1 , Roisin Bhamjee 1 & Christine Rodda 1,


1Department of Paediatrics, Sunshine Hospital, St Albans, Australia; 2Department of Paediatrics, University of Melbourne, Parkville, Australia; 3Melbourne Epicentre, Royal Melbourne Hospital, Parkville, Australia; 4Monash Pathology, Monash Health, Clayton, Australia; 5Department of Medicine, Monash University, Clayton, Australia.


Objective: There is no published data to demonstrate the efficacy and safety of a single bolus dose vitamin D in breastfed infants of vitamin D deficient mothers. We evaluated the efficacy and safety of this alternative approach in newborn infants <4 months of age.

Method: This single centre study was conducted from Aug 2013 to May 2014. Of 307 pregnant women diagnosed with vitamin D deficiency (25OHD<50 nmol/l) 70 were recruited. Their newborn infants were randomly assigned a daily dosing of 400 IU vitamin D for 4 months or a single dosing of 50 000 IU cholecalciferol. The primary objective was to ascertain which treatment was more effective in achieving repletion (25OHD>50 nmol/l) at 1–2 weeks and 3–4 months. The secondary objective was to determine safety using corrected calcium.

Results: Of 70 eligible infants, 36 received daily low dose and 34 received single high dose cholecalciferol. The mean vitamin D3 in the bolus group (154 nmol/l, 95% CI 131 to 177) was significantly higher than the daily group (48 nmol/l, 95% CI 42 to 54) (P<0.001) at 1–2 weeks of age, however the reverse was seen at 3–4 months (65 nmol/l, 95% CI 59 to 71) compared to the daily group (81 nmol/l, 95% CI 77 to 85) (P<0.008). Significantly more (100%) infants in the single bolus group achieved vitamin D replete status compared to the daily group at 1–2 weeks (31%) (P<0.001). By 3–4 months, both groups achieved similar vitamin D repletion status (daily 90.9% vs bolus 88.5%) (P=0.782).

Mean corrected calcium levels in the bolus group were within the normal range at 1–2 weeks (daily 2.81 mmol/l vs bolus 2.73 mmol/l) (P=0.005) and 3–4 months (daily 2.58 mmol/l vs bolus 2.55 mmol/l) (P=0.242) despite one-third to half changing from exclusive breastfeeding to mixed and exclusive formula feeding. Clinical parameters for vitamin D deficiency between both groups were similar.

Conclusion: Single bolus dosing of 50,000IU cholecalciferol achieves higher repletion rates of vitamin D3 at 1–2 weeks compared to daily dosing, although these were similar by 3–4 months. Single bolus dosing did not cause significant hypercalcaemia in the first 3–4 months of life.

Disclosure: The authors declared no competing interests.

Volume 4

7th International Conference on Children's Bone Health

Salzburg, Austria
27 Jun 2015 - 30 Jun 2015

ICCBH 

Browse other volumes

Article tools

My recent searches

No recent searches.